Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$0.67 USD
0.00 (-0.30%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.67 0.00 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GOSS 0.67 0.00(-0.30%)
Will GOSS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GOSS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GOSS
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
GOSS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
What Makes Gossamer Bio (GOSS) a New Buy Stock
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
Other News for GOSS
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call
Gossamer Bio assumed with an Outperform at Wedbush
Buy Rating Affirmed on Gossamer Bio with Promising Seralutinib Prospects in PAH Treatment Landscape